CSL Seqirus has welcomed the recent PBS listing of VAZKEPA (icosapent ethyl) for statin-treated patients with elevated triglycerides and at high risk of heart attack and stroke.
CSL welcomes new treatment for high-risk cardiovascular disease to the PBS
October 7, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Medicines Australia hardens stance as US pressure sharpens spotlight on PBS pricing
October 26, 2025 - - Latest News -
Immuron launches PROIBS in Australia to support people living with IBS
October 24, 2025 - - Australian Biotech -
Queensland to host AusBiotech International Conference and sector leadership strengthened with director re-election
October 24, 2025 - - Australian Biotech -
David Henderson to Lead Takeda’s Specialty Franchise in Oceania
October 24, 2025 - - Latest News -
New Zealand identified as a ‘major outlier’ in OECD medicines investment
October 24, 2025 - - BioPharma -
A perspective that rightly belongs in a time capsule from the 1990s
October 23, 2025 - - Latest News -
Global focus intensifies as AusBiotech strengthens trade, partnerships and international engagement
October 23, 2025 - - Australian Biotech
